Disease · MONDO_0001023

prolymphocytic leukemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prolymphocytic leukemia. Diseases, record MONDO_0001023. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001023

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prolymphocytic leukemia; Open Targets
Open Targets ID: MONDO_0001023; Open Targets
Other names: prolymphocytic leukaemia (B or T), prolymphocytic leukaemia (B or T-cell), prolymphocytic leukemia (B or T), prolymphocytic leukemia (B or T-cell); Open Targets
Disease Ontology: DOID:1039; Disease Ontology
MeSH: D015463; MeSH
NCI Thesaurus: C3181; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 16 of its 32 drugs, from ClinicalTrials.gov; Open Targets

Drugs32

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RITUXIMAB	CHEMBL1201576	Antibody	Phase 2	ClinicalTrials.gov	6	6	6	Drugs and targets
CYCLOPHOSPHAMIDE	CHEMBL1200796	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
FLUDARABINE	CHEMBL1568	Small molecule	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
ALEMTUZUMAB	CHEMBL1201587	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FILGRASTIM	CHEMBL1201567	Protein	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUDARABINE PHOSPHATE	CHEMBL1096882	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
LENALIDOMIDE	CHEMBL848	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
ALVOCIDIB	CHEMBL428690	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE)	CHEMBL2108981		Phase 2	ClinicalTrials.gov	1	1	0	Drugs and targets
IRINOTECAN	CHEMBL481	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 32

See all 32 drugs

Targets96

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
MS4A1	B-lymphocyte antigen CD20	3	B-lymphocyte antigen CD20 binding agent	Phase 2	https://conductscience.org/library/genes/931	Drugs and targets
TOP2A	DNA topoisomerase 2-alpha	3	DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor	Phase 2	https://conductscience.org/library/genes/7153	Drugs and targets
BTK	Tyrosine-protein kinase BTK	2	Tyrosine-protein kinase BTK inhibitor	Phase 1/2	https://conductscience.org/library/genes/695	Drugs and targets
CD22	B-cell receptor CD22	2	CD22 binding agent	Phase 1	https://conductscience.org/library/genes/933	Drugs and targets
EEF2	Elongation factor 2	2	Elongation factor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/1938	Drugs and targets
POLA1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	2	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 2	https://conductscience.org/library/genes/10714	Drugs and targets

1 to 10 of 96

See all 96 targets

Trials20

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00305682	Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant	Phase 2	295	2020-11-02	Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes	CYCLOPHOSPHAMIDE, FLUDARABINE, MYCOPHENOLATE MOFETIL, SIROLIMUS	Its record names the disease	ClinicalTrials.gov
NCT00472849	Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias	Phase 1/2	92	2013-11-26	Richter's Transformation, Leukemia	CYTARABINE, FLUDARABINE, OXALIPLATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT01217749	Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLL	Phase 1/2	71	2015-04-16	B-cell Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocyctic Leukemia, Richter's Transformation	IBRUTINIB, OFATUMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00098371	Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia	Phase 2	64	2016-10-24	B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia	ALVOCIDIB	Its record names the disease	ClinicalTrials.gov
NCT00452374	Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL	Phase 1/2	48	2011-08-29	Leukemia	CYTARABINE, FLUDARABINE, OXALIPLATIN, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT00077922	Anti-Tac(Fv)-PE38 (LMB-2) to Treat Chronic Lymphocytic Leukemia	Phase 2	15	2012-11-15	Leukemia, Lymphocytic, Chronic	LMB-2	Its record names the disease	ClinicalTrials.gov
NCT00587457	A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia	Phase 1	11	2017-04-12	Leukemia, Lymphoma, Chronic Lymphocytic, Leukemia, Prolymphocytic Leukemia, Small, Lymphocytic Lymphoma, Moxetumomab Pasudotox	MOXETUMOMAB PASUDOTOX	Its record names the disease	ClinicalTrials.gov
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	Phase 2	3	2017-03-21	Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia	LENALIDOMIDE, RITUXIMAB	Its record names the disease	ClinicalTrials.gov
NCT02296918	Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLL	Phase 1	69		Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia	ACALABRUTINIB, OBINUTUZUMAB, RITUXIMAB, VENETOCLAX	Its record names the disease	ClinicalTrials.gov
NCT00457860	Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease	Phase 1	50		Leukemia	MOXETUMOMAB PASUDOTOX	Its record names the disease	ClinicalTrials.gov

1 to 10 of 20

See all 20 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
OFAR (Phase I) vs OFAR MTD (Phase II): serious adverse events	8 of 12	15 of 78	90	NCT00472849

Source Trial comparisons

Papers from its trials18

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31915195	RESULT	1	PubMed
24990615	RESULT	1	PubMed
23512246	RESULT	1	PubMed
22289993	RESULT	1	PubMed
21296675	RESULT	1	PubMed
19826119	RESULT	1	PubMed
19167681	RESULT	1	PubMed
16061911	RESULT	1	PubMed
11986207	RESULT	1	PubMed
34608724	DERIVED	1	PubMed

1 to 10 of 18

See all 18 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001023

GET https://conductscience.org/api/diseases/v1/MONDO_0001023/drugs?page=2

API reference For AI assistants